European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/european-chmp-recommends-sarclisa-isatuximab-ndmm)